Optimizing Skyrizi Prior Authorization for Neurology Patients

While Skyrizi (risankizumab), an IL-23 inhibitor, is primarily indicated for inflammatory conditions like plaque psoriasis and Crohn's disease, managing Skyrizi prior authorization for neurology patients with co-morbidities requires a robust, integrated approach to maintain continuity of care.

Neurology practices frequently manage patients with complex multi-system inflammatory diseases where medications like Skyrizi may be prescribed by other specialists. Efficiently navigating the prior authorization landscape for these specialty drugs, even when not directly treating a neurological condition, is crucial for patient access and revenue cycle integrity across the health system.

The Administrative Intersection of Skyrizi and Neurology Practice

Skyrizi (risankizumab) is indicated for plaque psoriasis, psoriatic arthritis, and Crohn's disease. While not a primary neurological therapeutic, neurology practices often encounter patients with these co-morbid conditions. Managing prior authorization for such cross-specialty medications necessitates a coordinated approach to ensure patient access to all necessary treatments and to prevent administrative backlogs within the neurology department.

Navigating the Complex Prior Authorization Landscape in Neurology

Neurology prior authorization is characterized by its high volume of specialty drugs and complex documentation requirements. Key categories include MS disease-modifying therapies (e.g., ocrelizumab, natalizumab), Alzheimer's disease therapeutics (e.g., lecanemab), CGRP migraine prevention biologics (e.g., erenumab, fremanezumab), and advanced imaging. This existing complexity is further amplified when managing PAs for non-neurological drugs like Skyrizi within a neurology patient's overall care plan.

Key Documentation Considerations for Specialty Drugs in Neurology

Diagnosis confirmation per established criteria (e.g., McDonald criteria for MS, amyloid PET for Alzheimer's disease).
Documentation of disease severity, progression metrics (e.g., EDSS), and impact on daily function.
Evidence of prior treatment failures or compliance with step therapy protocols, particularly for high-cost biologics.
Relevant imaging or biomarker results, such as MRI findings for ARIA screening or CSF biomarker confirmation for anti-amyloid antibodies.
Coordination of care documentation, including treatment plans and supporting clinical notes from other prescribing specialties.

Common PA Challenges for Cross-Specialty Medications

For drugs like Skyrizi, when prescribed for co-morbid conditions, neurology practices may face challenges such as navigating payer policies that are not typical for neurological PAs, coordinating documentation across disparate EMRs from different specialties, and managing periodic re-authorizations. Denial reasons can often stem from incomplete documentation of step therapy compliance or gaps in meeting specific NCD/LCD criteria relevant to the drug's primary indication.

Klivira's Role in Streamlining Prior Authorization Across Specialties

Klivira's platform provides a robust solution for managing the intricate PA landscape in neurology, including for patients on cross-specialty medications like Skyrizi. Our system integrates with EMRs via SMART on FHIR, automates data extraction, and connects directly to payer portals using X12 278 and Da Vinci PAS. This ensures all necessary documentation, from AAN Practice Guideline-aware step-therapy logic for MS DMTs to biomarker confirmation for Alzheimer's therapeutics, is accurately submitted, reducing administrative burden and accelerating patient access.

Frequently asked questions

Is Skyrizi used to treat neurological conditions?

No, Skyrizi (risankizumab) is an IL-23 inhibitor whose approved indications are for plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is not indicated for primary neurological conditions. However, neurology patients may have these co-morbid conditions, leading to its presence in their medication regimen.

How does Klivira handle prior authorization for drugs like Skyrizi when a neurologist is part of the care team?

Klivira automates PA workflows across specialties within a health system. Our platform ensures that all necessary documentation, regardless of the prescribing department, is collected, validated, and submitted to payers. This supports integrated care models by streamlining the PA process for all specialty drugs, including those for co-morbid conditions managed by multiple specialists.

What are common PA challenges for neurology practices when managing patients on non-neurological specialty drugs?

Challenges include navigating payer policies specific to non-neurological indications, coordinating the collection of documentation from different specialty EHRs, and managing the periodic re-authorization requirements for chronic therapies. These complexities can lead to delays in care and increased administrative overhead for the neurology team.

Does Klivira integrate with EMRs to pull patient data for Skyrizi PA?

Yes, Klivira integrates with leading EMRs via SMART on FHIR standards to automatically pull relevant patient data. This capability streamlines the documentation process for any specialty drug, including gathering clinical information for co-morbid conditions that support prior authorization submissions.

Are there specific guidelines for Skyrizi prior authorization that neurology teams should be aware of?

Prior authorization guidelines for Skyrizi are specific to its approved indications (plaque psoriasis, psoriatic arthritis, Crohn's disease). While neurology teams are not directly applying these, they should ensure access to comprehensive documentation from the prescribing specialist to support these guidelines effectively for payer approval, especially when coordinating care for patients with co-morbidities.